6 Nov 2026, 14:49
Securities Administration—
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 6 Nov 2026, 14:49 | Updated Top 20 Option Holders Report | Securities Administration | — | 03002 | |
| 6 Nov 2026, 12:19 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 6 Nov 2026, 11:55 | Top 20 Optionholders and Distribution List | Securities Administration | — | 03002, 06009 | |
| 6 Nov 2026, 11:53 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 6 Nov 2026, 09:44 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 4 Nov 2026, 08:51 | Update - Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 4 Nov 2026, 08:47 | Update - Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 4 Nov 2026, 08:41 | Update - Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 4 Nov 2026, 08:37 | Prospectus - Placement options and JLM options | Securities Administration | — | 06010 | |
| 2 Nov 2026, 08:17 | FDA Clearance for Vanderbilt Health Clinical Trial in AML | Company Update | — | 11001 | |
| 30 Oct 2026, 09:11 | Listing Rule waiver to allow quotation of PERAQ options | Company Administration | — | 12008, 12016 | |
| 23 Oct 2026, 09:46 | Completion of HMBD-002 Drug Product Manufacture | Company Update | — | 11001 | |
| 20 Oct 2026, 11:15 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19001, 19006 | |
| 20 Oct 2026, 08:42 | IVX: Photosoft & Novel Immunotherapy Collab Partnership | Other | — | — | |
| 20 Oct 2026, 08:23 | Percheron and Invion to Explore Cancer Combination Therapy | Company Update | — | 11001 | |
| 15 Oct 2026, 09:36 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 15 Oct 2026, 08:17 | Notice under S708A | Securities Administration | — | 06018 | |
| 14 Oct 2026, 09:29 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 14 Oct 2026, 09:20 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 8 Oct 2026, 13:12 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 8 Oct 2026, 13:09 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 7 Oct 2026, 15:40 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 7 Oct 2026, 09:47 | Annual General Meeting - Management Presentation | Presentations | — | 03026, 15002 | |
| 7 Oct 2026, 09:43 | Annual General Meeting - Chair Address | Presentations | — | 03026, 15002 | |
| 5 Oct 2026, 17:03 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 5 Oct 2026, 08:24 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 5 Oct 2026, 08:24 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 5 Oct 2026, 08:21 | Dr Michael Baker Commences as CEO and MD | Company Administration | — | 12008, 12019 | |
| 8 Sept 2026, 08:36 | Notice under S708A | Securities Administration | — | 06018 | |
| 7 Sept 2026, 08:25 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 7 Sept 2026, 08:24 | 2026 Notice of Annual General Meeting | Meetings & Governance | — | 08001, 08004 | |
| 1 Sept 2026, 11:01 | Percheron Therapeutics Limited Corporate Presentation | Presentations | — | 03026 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Percheron raises $2.3m to fully fund clinical trial in AML | Capital Raising | MS | 06003, 06009, 08006, 09014 | |
| 31 Aug 2026, 17:24 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 31 Aug 2026, 17:22 | Transitional appointment of Executive Director | Company Administration | — | 12001 | |
| 31 Aug 2026, 17:02 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 31 Aug 2026, 17:01 | Notification of cessation of securities - PER | Securities Administration | — | 06027 | |
| 31 Aug 2026, 12:06 | Percheron receives $0.70m R&D Tax Incentive Rebate | Company Administration | — | 12008 | |
| 28 Aug 2026, 09:01 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 28 Aug 2026, 08:11 | Vanderbilt Health to conduct clinical trial of HMBD-002 | Company Update | MS | 11001 | |
| 19 Aug 2026, 17:24 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 19 Aug 2026, 11:38 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 19 Aug 2026, 11:33 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 14 Aug 2026, 14:46 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 12 Aug 2026, 08:16 | Notice of date of AGM and other relevant dates | Meetings & Governance | — | 08006 | |
| 10 Aug 2026, 08:24 | Percheron Therapeutics Announces CEO Succession | Company Administration | MS | 12019 | |
| 31 July 2026, 08:29 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 |